TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07783269: A Single-Arm, Open-Label, Multi-Center, Phase Ib Basket Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTA313 in Participants With Active Autoimmune Diseases

Sponsor: Imviva Bio · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 81 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,442,880

Rescue Site Savings

+$5,567,024

Unlock Full NCT07783269 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07783269 Rescue Dossier →